Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.
We have determined the expression of transforming growth factor alpha (TGF alpha), amphiregulin (AR), CRIPTO, the epidermal growth factor receptor (EGFR), erbB-2, erbB-3, and tumor angiogenesis in a series of 195 patients with stage I-IIIA non-small cell lung cancer (NSCLC) treated with radical surgery to define their usefulness as prognostic indicators of survival. A variable degree of specific staining in cancer cells was observed for the three growth factors and for the three growth factor receptors in the majority of NSCLC patients. A statistically significant association between overexpression of TGF alpha, AR, and CRIPTO was observed. Enhanced expression of AR was significantly correlated with enhanced expression of erbB-2 and advanced T-stage. A direct association was also detected for overexpression of TGF alpha and of erbB-2 or erbB-3, respectively. Sex, tumor size, nodal status, stage, microvessel count, as a measure of neovascularization, and AR overexpression significantly correlated with overall survival at univariate analysis. In a Cox multivariate analysis, the only characteristics with an independent prognostic effect on OAS were microvessel count [relative hazard (RH), 6.61; P < 0.00001), nodal status (RH, 1.59; P = 0.0013), and AR overexpression (RH, 1.72; P = 0.02). These results suggest that evaluation of neoangiogenesis and of certain growth factors, such as AR, can be useful in addition to conventional pathological staging to select high-risk NSCLC patients who may benefit from post-surgical systemic therapies.
Fontanini
G
G
Dipartimento di Oncologia, Università di Pisa, Italy.
De Laurentiis
M
M
Vignati
S
S
Chinè
S
S
Lucchi
M
M
Silvestri
V
V
Mussi
A
A
De Placido
S
S
Tortora
G
G
Bianco
A R
AR
Gullick
W
W
Angeletti
C A
CA
Bevilacqua
G
G
Ciardiello
F
F
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D066258:Amphiregulin; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply / Q000737:chemistry* / Q000473:pathology; D066255:EGF Family of Proteins; D005260:Female; D006023:Glycoproteins / Q000032:analysis*; D006133:Growth Substances / Q000032:analysis*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D008175:Lung Neoplasms / Q000098:blood supply / Q000737:chemistry* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic; D011379:Prognosis; D017978:Receptors, Growth Factor / Q000032:analysis*; D015996:Survival Rate; D016211:Transforming Growth Factor alpha / Q000032:analysis
C587848:AREG protein, human; D066258:Amphiregulin; D066255:EGF Family of Proteins; D006023:Glycoproteins; D006133:Growth Substances; D036341:Intercellular Signaling Peptides and Proteins; D017978:Receptors, Growth Factor; D016211:Transforming Growth Factor alpha